Titelbild

Management Team

Topas Therapeutics is led by a highly qualified team with scientific depth and decades of experience in drug development and operational management.

 
Portrait

Klaus Martin, PhD, Chief Executive Officer

Klaus joined Topas Therapeutics in August 2020. He previously was President of Toronto-based Apobiologix, Apotex’ biotechnology division, where he led the development, sales & marketing and operational organization and played a key role in Apobiologix’ registrations, partnerships and in achieving a market leadership position. Prior to that, he was Chief Scientific Officer of Polpharma Biologics, where he set up the organization and managed all portfolio, licensing and late-stage development activities for biosimilar and innovative biologics. Previously, he worked at Sandoz Biopharmaceuticals, both in Germany and Austria, most recently serving as Global Head Business Development & Licensing (BD&L) and Portfolio Management where he drove the portfolio strategy and managed all licensing negotiations. Klaus holds a PhD in molecular genetics from Cambridge University and Darwin College, United Kingdom.

 
Portrait

Klaus Martin, PhD, Chief Executive Officer

Klaus joined Topas Therapeutics in August 2020. He previously was President of Toronto-based Apobiologix, Apotex’ biotechnology division, where he led the development, sales & marketing and operational organization and played a key role in Apobiologix’ registrations, partnerships and in achieving a market leadership position. Prior to that, he was Chief Scientific Officer of Polpharma Biologics, where he set up the organization and managed all portfolio, licensing and late-stage development activities for biosimilar and innovative biologics. Previously, he worked at Sandoz Biopharmaceuticals, both in Germany and Austria, most recently serving as Global Head Business Development & Licensing (BD&L) and Portfolio Management where he drove the portfolio strategy and managed all licensing negotiations. Klaus holds a PhD in molecular genetics from Cambridge University and Darwin College, United Kingdom.

 
Portrait

Christian Schröter, PhD, Chief Operating Officer

Christian joined Topas Therapeutics in June 2022 and is responsible for all CMC (chemistry, manufacturing & controls) activities, as well as project management. He spent 22 years at Merck in pharmaceutical R&D and operations, most recently as Head of Strategy, Global Healthcare Operations. His experience covers the healthcare value chain from late-stage research, pharmaceutical development and sterile production to franchise support and operations strategy. Christian is trained as a biochemist and received his PhD in immunology from Eberhard-Karls-University in Tübingen, Germany.

 
Portrait

Christian Schröter, PhD, Chief Operating Officer

Christian joined Topas Therapeutics in June 2022 and is responsible for all CMC (chemistry, manufacturing & controls) activities, as well as project management. He spent 22 years at Merck in pharmaceutical R&D and operations, most recently as Head of Strategy, Global Healthcare Operations. His experience covers the healthcare value chain from late-stage research, pharmaceutical development and sterile production to franchise support and operations strategy. Christian is trained as a biochemist and received his PhD in immunology from Eberhard-Karls-University in Tübingen, Germany.

 
Portrait

Cristina de Min, MD, Chief Medical Officer

Cristina joined Topas in September 2021 and is responsible for all clinical development programs. She spent 11 years at Roche in various executive positions, including Life Cycle Leader for the development of the IL-6 receptor antagonist tocilizumab (Actemra) for rheumatic diseases. She also served as Medical Director of Roche’s affiliate in Italy. Following Roche, she joined Novimmune, serving for nine years as Chief Medical Officer before the company was acquired by Swedish Orphan Biovitrum (SOBI). At Novimmune, she set up the clinical development department and was responsible for the global development strategy for drug candidates from translational activities through clinical development and registration. Cristina received her M.D. and board certification in endocrinology from the University of Milan.

 
Portrait

Cristina de Min, MD, Chief Medical Officer

Cristina joined Topas in September 2021 and is responsible for all clinical development programs. She spent 11 years at Roche in various executive positions, including Life Cycle Leader for the development of the IL-6 receptor antagonist tocilizumab (Actemra) for rheumatic diseases. She also served as Medical Director of Roche’s affiliate in Italy. Following Roche, she joined Novimmune, serving for nine years as Chief Medical Officer before the company was acquired by Swedish Orphan Biovitrum (SOBI). At Novimmune, she set up the clinical development department and was responsible for the global development strategy for drug candidates from translational activities through clinical development and registration. Cristina received her M.D. and board certification in endocrinology from the University of Milan.

 
Portrait

Reinaldo Digigow, PhD, Head of Nanotechnology & Head of CMC

Reinaldo focuses on nanoparticle design and synthesis, on analytics and on the strategy and execution of CMC-relevant drug product development at Topas Therapeutics. He has worked at pharmaceutical companies and analytical chemistry labs in Brazil and Europe. Before joining Topas, Reinaldo was Lab Head Analytical Development, CMC Center Europe at Takeda Pharmaceuticals. He was trained as a pharmacist and biochemist and received his PhD from the University of Fribourg, Switzerland.

 
Portrait

Reinaldo Digigow, PhD, Head of Nanotechnology & Head of CMC

Reinaldo focuses on nanoparticle design and synthesis, on analytics and on the strategy and execution of CMC-relevant drug product development at Topas Therapeutics. He has worked at pharmaceutical companies and analytical chemistry labs in Brazil and Europe. Before joining Topas, Reinaldo was Lab Head Analytical Development, CMC Center Europe at Takeda Pharmaceuticals. He was trained as a pharmacist and biochemist and received his PhD from the University of Fribourg, Switzerland.

 
Portrait

Sabine Fleischer, MD, Head of Translational Medicine

Sabine joined Topas Therapeutics in November 2015 as Head of Translational Medicine. Since 2009, she has been Scientific Coordinator of the Institute of Neuroimmunology and Multiple Sclerosis in Hamburg, focusing on translational research projects and early clinical MS studies in the framework of the research consortium NEU. Sabine studied medicine at the Universities of Giessen, Göttingen and Würzburg. As a scholar of the German Research Foundation, she trained in molecular biology and immunology at the Institute of Biochemistry in Munich and the Basel Institute for Immunology and was a postdoc at the Institute of Immunology in Ulm.

 
Portrait

Sabine Fleischer, MD, Head of Translational Medicine

Sabine joined Topas Therapeutics in November 2015 as Head of Translational Medicine. Since 2009, she has been Scientific Coordinator of the Institute of Neuroimmunology and Multiple Sclerosis in Hamburg, focusing on translational research projects and early clinical MS studies in the framework of the research consortium NEU. Sabine studied medicine at the Universities of Giessen, Göttingen and Würzburg. As a scholar of the German Research Foundation, she trained in molecular biology and immunology at the Institute of Biochemistry in Munich and the Basel Institute for Immunology and was a postdoc at the Institute of Immunology in Ulm.

 
Portrait

Barbara Metzler, PhD, Head of Biology

Barbara has over 25 years of experience in immune tolerance and immune regulation research in academia and industry. Before joining Topas Therapeutics, she led a research lab and numerous projects in autoimmunity and transplantation at Novartis. Her postgraduate and postdoctoral studies were related to T cell regulation, with an early focus on peptide-induced tolerance in models of autoimmunity. Barbara has a BSc (Hons) in biochemistry from Edinburgh University and a PhD in immunology from the University of Cambridge.

 
Portrait

Barbara Metzler, PhD, Head of Biology

Barbara has over 25 years of experience in immune tolerance and immune regulation research in academia and industry. Before joining Topas Therapeutics, she led a research lab and numerous projects in autoimmunity and transplantation at Novartis. Her postgraduate and postdoctoral studies were related to T cell regulation, with an early focus on peptide-induced tolerance in models of autoimmunity. Barbara has a BSc (Hons) in biochemistry from Edinburgh University and a PhD in immunology from the University of Cambridge.